Position in TEVA
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$13,253,008
+$1,799,397 QoQ
Shares Held
391,175
+2.9% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#131
of 671 holders
Holding Since
Mar 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TEVA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Swedbank AB holds $548,199,348 across 6 Drug Manufacturers - Specialty & Generic names. TEVA ranks #5 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
322,995 | $175,008,380 | |
| 2 | LNTH |
Lantheus Holdings, Inc.
|
1,201,243 | $133,265,898 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
651,082 | $109,733,360 | |
| 4 | ZTS |
Zoetis Inc.
|
1,485,141 | $106,722,232 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
This page
|
391,175 | $13,253,008 | |
| 6 | INDV |
Indivior Pharmaceuticals, Inc.
|
249,000 | $10,216,470 |
All Filings in TEVA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,253,008 | 391,175 | Shares | Defined | 2026-07-15 | |
| 2026-03-31 | $11,453,611 | 380,266 | Shares | Defined | 2026-04-29 | |
| 2025-06-30 | $1,854,544 | 110,653 | Shares | Defined | 2025-07-10 | |
| 2024-12-31 | $2,411,373 | 109,409 | Shares | Defined | 2025-01-22 | |
| 2024-09-30 | $1,971,549 | 109,409 | Shares | Defined | 2024-10-11 | |
| 2024-06-30 | $1,828,287 | 112,510 | Shares | Defined | 2024-07-11 | |
| 2024-03-31 | $1,623,919 | 115,090 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $1,053,739 | 100,933 | Shares | Defined | 2024-12-06 | |
| 2023-09-30 | $1,057,668 | 103,693 | Shares | Defined | 2024-12-06 | |
| 2021-03-31 | $1,188,123 | 102,957 | Shares | Defined | 2024-12-06 | |
| No filing history on record for this holder in this stock. | ||||||